Are mesenchymal stem cells and derived extracellular vesicles valuable to halt the COVID-19 inflammatory cascade? Current evidence and future perspectives.
Are mesenchymal stem cells and derived extracellular vesicles valuable to halt the COVID-19 inflammatory cascade? Current evidence and future perspectives.
复制标题
DOI：
10.1136/thoraxjnl-2020-215717
复制
发表时间：
2021-03
期刊：
影响因子：
10
通讯作者：
Roura S
中科院分区：
文献类型：
--
作者：
Monguió-Tortajada M;Bayes-Genis A;Rosell A;Roura S
对COVID-19患者的临床管理包括感染预防、控制措施和支持性护理，包括补充氧气和机械通气支持。1 2如果不考虑血管中心性特征进行专业和个体化管理，3 20%的COVID-19患者出现急性呼吸窘迫综合征（ARDS; 14.8%的住院患者4），即使年龄不高或未受既存合并症或慢性疾病的影响，也可能最终进展为多器官衰竭和死亡。在这些患者中，SARS-CoV-2感染激活了先天性和适应性免疫反应，引起大量促炎细胞因子和趋化因子的产生，导致临床表现。（即持续高热、淋巴结病、肝脾肿大、血细胞减少、高铁蛋白血症、中枢神经系统异常、低白蛋白血症和毛细血管渗漏）与其他全身性，不受控制的细胞因子释放综合征（CRS）（图1）。因此，目前正在探索通过使用适当的免疫抑制和免疫调节药物来管理COVID-19的潜在炎症并发症。8到目前为止，各种具有多种药理作用和治疗功效的新型和再利用药物已被纳入对抗COVID-19的潜在药物组合中。9 10例如，在初步测试的抗病毒药物中，remdesivir显示出最佳疗效，在缩短恢复时间和下呼吸道感染证据方面有显着改善。11于2020年5月1日获发紧急使用授权，用于治疗因严重疾病住院的COVID-19患者，
Clinical management of patients suffering from COVID-19 includes infection prevention, control measures and supportive care, including supplemental oxygen and mechanical ventilatory support. 1 2 If not expertly and individually managed with consideration for vasocentric features, 3 20% of COVID-19 patients who exhibit acute respiratory distress syndrome (ARDS; 14.8% of hospitalised patients 4) may eventually progress to multiorgan failure and death, even when not of advanced age or predisposed by pre-existing comorbidities or chronic diseases. 5 In these patients, infection by SARS-CoV-2 activates both the innate and adaptive immune responses, provoking the production of large amounts of proinflammatory cytokines and chemokines, resulting in a clinical presentation (ie, unremitting high fever, lymphadenopathy, hepatosplenomegaly, cytopenia, hyperferritinaemia, central nervous system abnormalities, hypoalbuminaemia and capillary leak) similar to other systemic, uncontrolled cytokine release syndromes (CRS)(figure 1). 6 7 Thus, at present, management of the potential inflammatory complications of COVID-19 by using appropriate immunosuppressive and immunomodulatory drugs is being explored. 8To date, a variety of novel and repurposed drugs with multiple pharmacological effects and therapeutic efficacies have been included in the potential armamentarium against COVID-19. 9 10 For instance, among the antivirals preliminary tested, remdesivir has showing the best efficacy, with significant improvements in shortening the time to recovery and evidence of lower respiratory tract infection. 11 It was issued an emergency use authorisation on 1 May 2020 for the treatment of COVID-19 patients hospitalised with severe disease by the Food and
登录
查看更多内容
DOI：
10.1016/s2213-2600(18)30418-1
发表时间：
2019-03
期刊：
The Lancet. Respiratory medicine
影响因子：
--
作者：
Matthay MA;Calfee CS;Zhuo H;Thompson BT;Wilson JG;Levitt JE;Rogers AJ;Gotts JE;Wiener-Kronish JP;Bajwa EK;Donahoe MP;McVerry BJ;Ortiz LA;Exline M;Christman JW;Abbott J;Delucchi KL;Caballero L;McMillan M;McKenna DH;Liu KD
通讯作者：
Liu KD
影响因子：
12.8
作者：
Chen, Jiajia;Hu, Chenxia;Li, Lanjuan
通讯作者：
Li, Lanjuan
影响因子：
158.5
作者：
Ackermann, Maximilian;Verleden, Stijn E.;Jonigk, Danny
通讯作者：
Jonigk, Danny
ACE2(-) 间充质干细胞移植可改善 COVID-19 肺炎患者的预后
影响因子：
7.4
作者：
Leng, Zikuan;Zhu, Rongjia;Zhao, Robert Chunhua
通讯作者：
Zhao, Robert Chunhua
影响因子：
10
作者：
Gupta N;Krasnodembskaya A;Kapetanaki M;Mouded M;Tan X;Serikov V;Matthay MA
通讯作者：
Matthay MA